EGFR-IN-5

• CAT Number: I019528
• CAS Number: 2225887-26-1
• Molecular Formula: C₃₁H₃₈FN₉O
• Molecular Weight: 571.69
• Purity: ≥95%
• Target: Protein Tyrosine Kinase/RTK
• IUPAC Name: [1-[6-[[5-[4-(dimethylamino)piperidin-1-yl]pyridin-2-yl]amino]-2-(4-fluoroanilino)pyrido[3,4-d]pyrimidin-4-yl]piperidin-4-yl]methanol
• InChI: 1S/C31H38FN9O/c1-39(2)24-11-15-40(16-12-24)25-7-8-28(33-18-25)37-29-17-26-27(19-34-29)36-31(35-23-5-3-22(32)4-6-23)38-30(26)41-13-9-21(20-42)10-14-41/h3-8,17-19,21,24,42H,9-16,20H2,1-2H3,(H,33,34,37)(H,35,36,38)
• InChIKey: DXOUQSZKEPSXBC-UHFFFAOYSA-N
• SMILES: CN(C)C1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C(=C3)C(=NC(=N4)NC5=CC=C(C=C5)F)N6CCC(CC6)CO

EGFR-IN-5 (Cat No.: I019528) is a selective epidermal growth factor receptor (EGFR) inhibitor that targets EGFR-mediated signaling pathways involved in cell proliferation, survival, and tumorigenesis. By inhibiting EGFR tyrosine kinase activity, EGFR-IN-5 disrupts downstream pathways such as PI3K/AKT and MAPK, making it a valuable tool in cancer research. It is particularly relevant for studying non-small cell lung cancer (NSCLC) and other EGFR-driven malignancies. EGFR-IN-5 holds potential for drug discovery and therapeutic development, especially in overcoming resistance to first-generation EGFR inhibitors.

Reference

[1]. Zhang H, et al. Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. Eur J Med Chem. 2018 Mar 25;148:221-237.